August 9, 2022 – Page 2 – Indonesia News Gazette

August 9, 2022

Neeyamo Announces Season 2 of Working Beyond Borders

The final pitstop of season 1 of Neeyamo’s Working Beyond Borders took place in Singapore on Aug. 4.

Neeyamo announces Season 2 of Working Beyond Borders

SINGAPORE, Aug. 08, 2022 (GLOBE NEWSWIRE) — Neeyamo is delighted to announce the second season of Working Beyond Borders with a spotlight on the impact of Employer of Record (EOR) on the future of work. This follows the successful completion of season 1 of Working Beyond Borders with its fifth and final pitstop in Singapore on Aug. 4.

Working Beyond Borders is an invite-only event designed to promote networking and collaboration among the brightest minds in the HR, global payroll, and the EOR industry. WBB season 1 was hosted across London, Milan, Manila, and Buenos Aires before the Singapore pitstop to ignite discussions about managing a global workforce and to provide in-depth insights into the rapidly changing payroll landscape.

Businesses today are undergoing a transformational shift. Global expansion is a common thread among successful organizations. However, handling payroll for a global workforce presents unforeseen challenges. With their legacy technologies and processes, organizations often struggle to cope with daily demands.

The Singapore pitstop addressed these unforeseen challenges, including a session on “Key global trends impacting payroll and HR that transform the modern-day workplace” that sparked enthusiastic conversations. Of interest were topics on the desire for a more diverse workforce, the introduction of next-gen technology in global payroll, and the demand for a cloud-based payroll solution that led to a shift in HR professionals’ working habits and skillsets.

Rangarajan Seshadri, CEO, Neeyamo, said, “Standardization in HR processes and payroll is often a challenge for many businesses due to varying compliance requirements and the lack of an integrated tech ecosystem. Neeyamo believes that through season 1 of Working Beyond Borders, we created an opportunity for companies to learn, unlearn and re-learn the future of HR and global payroll. With the focus on EOR in season 2, the emphasis will be on helping companies access talent globally and navigate the future of work.”

Please click here to know more about the event.

About Neeyamo:

Neeyamo is a leading technology-enabled global payroll and EOR solutions provider for multinational and micro-multinational corporations worldwide. With an extensive team of professionals serving clients across 190+ countries, Neeyamo leverages its unique service-based model and functionality-rich, next-generation HR & payroll products portfolio to help organizations enable agile and scalable business. To know more, visit www.neeyamo.com.

Media Contact: corporate.communications@neeyamo.com

The final pitstop of season 1 of Neeyamo’s Working Beyond Borders took place in Singapore on August

This content was issued through the press release distribution service at Newswire.com.

Attachment

Neeyamo announces Season 2 of Working Beyond Borders

August 9, 2022

Peter Lake, the World’s Only Anonymous Singer-Songwriter, Releases New Single ACORNS, a Song He Wrote in Response to the Current Recession Fears and Economic Malaise

Says Lake, ‘As a musician, we have a job to document the signs of the times, rather than just release and promote songs for economic gain.’ Featuring guitar and banjo of Guns ‘n Roses member Richard Fortus, the song is now available globally.

ACORNS, By Peter Lake

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) — In his newly released single called ACORNS, Peter Lake attempts to give a voice to the sign of the times. Without forcing a judgment on a range of topics from the stock market to fossil fuels, Lake summarizes the range of topics that seem to define the times, and which he feels should be cataloged for our “collective memory.” Lake suggests that history is often forgotten, but music can be a special tool that helps us remember. Mr. Lake’s decision to release the song, merely weeks after two successive singles, reflects his desire to write about contemporary issues as they are happening, a practice he urges other musicians to follow.

Says Lake:

“ACORNS is all about how times change, and how this is neither good nor bad, but just the way of the world. I hear about recession and everything getting expensive. I don’t know if these things are true or lasting. I don’t even really know what recession means! But there is a vibe that things aren’t going well, and we need to get ready for something, and the song tries to get at the new vibe.”

Lake goes on, explaining celebrity culture has made music a means of becoming famous. Lake notes that a hundred years ago, it would be “crazy” to go into music for money. “I think music should return to what it was originally, songs that are stories and songs that are about history, current events and the human condition. And most importantly, songs that could be sung in communities and that stand apart from whoever wrote them.”

ACORNS is now available globally wherever music is streamed. To learn more about the music of Peter Lake, please visit his social media. @peterlakemusic

All inquiries can be directed to PL@peterlakesounds.com.

Artist Biography:

Peter Lake is a Canadian-born, New York City-based singer-songwriter who revels in anonymity. In an age where privacy is rare, Peter is convinced that his ability to create music is protected by his anonymity, and by working with unconventional partners in an attempt to avoid the constraints of traditional record deals, which often consider recorded music as a means to promote tours.

Peter is the first of a kind: an artist who will only do live concerts via a web-based platform, thereby freeing him to focus exclusively on writing and recording new, original music that crosses all genres. In the process, Peter has assembled one of the largest singer-songwriter catalogs in the industry. His musical influences include Neil Young, Max Martin, David Bowie, Motown, and Drake.

It’s no surprise that his songs are hard to place, often flying between (and combining) House beats, crunchy guitar riffs and “traditional chants and natural sounds.”

From what we learned in our conversations with the artist, humility does not come naturally. On the other hand, it’s hard to consider his views as arrogant, given the intense sincerity with which he describes his plans. When asked about his goal, he replied as follows:

“My goal is to wake up every day and make music, and one day through that process, write and perform what will later be seen as the greatest song in history, a song that will define humankind for centuries.”

Related Images

Image 1: ACORNS, By Peter Lake

Single Album Art

Image 2: Peter Lake

Peter Lake recording at Quad Studios in New York City.

This content was issued through the press release distribution service at Newswire.com.

Attachment

ACORNS, By Peter Lake

August 9, 2022

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

DREAM enrollment complete, 12-month clinical data expected in fall of 2023

Mont-Saint-Guibert, Belgium – August 8, 2022, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2022.

Second Quarter 2022 Financial and Operating Highlights

Completed enrollment in DREAM U.S. pivotal trial; expect 12-month clinical data in the fall of 2023 and regulatory approval in the first half of 2024
Generated revenue of €935,000 from the commercialization of Genio® in Europe, primarily in Germany, which represents growth of more than five times the amount achieved in the second quarter of 2021
Activated 11 new implanting sites in Germany during the second quarter, bringing the total to 26 as of June 30, 2022; expecting to have at least 35 active implanting sites by the end of 2022
Received FDA approval of IDE submission to commence the ACCCESS study to treat complete concentric collapse (CCC) patients in the U.S., with first patient implant expected in the fourth quarter of 2022
Received FDA approval of the next generation Genio® 2.1 system for use in the DREAM study and CE mark for use in commercial patients in Europe; this improves patient comfort and compliance with a new smartphone application and upgraded external activation chip, which leverages Nyxoah’s scalable platform to continuously enhance patient comfort and therapy efficacy without requiring a new implant
Partnered with Acurable to distribute the AcuPebble SA100 wearable home sleep test to OSA patients in Germany; launch is expected in the fourth quarter of 2022
Included in the newly formed Euronext Tech Leaders Index, which is composed of 100+ innovative and high-growth technology companies with greater than €1 trillion in aggregate market capitalization

“We made significant progress on all of our key strategic priorities this quarter, including activating 11 new commercial sites in Germany, completing enrollment in our DREAM trial, and receiving approval for our ACCCESS IDE,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “From a commercial standpoint, our second quarter performance showing 42% quarter-over-quarter growth strengthens our confidence that we will achieve market leadership status in Germany by the end of 2022.”

“As the only commercially available hypoglossal nerve stimulation (HGNS) therapy approved for the treatment of CCC patients, we are encouraged by the first strong results from patients who are six months post-implantation. These results, combined with no longer having to perform a drug-induced sleep endoscopy (DISE) procedure prior to implant, are driving physicians to recommend Genio for their CCC and non-CCC patients,” continued Mr. Taelman.

Mr. Taelman concluded, “In the meantime, we have already begun investing in our U.S. market access organization. As for our ACCCESS study, we expect to implant the first patients before year end.”

Second Quarter and First Half 2022 Results

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION – INTERIM CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2022 (in thousands)

	For the three months ended June 30		For the six months ended June 30
	2022	2021	2022	2021

Revenue	€ 935	€ 170	€ 1 595	€ 355
Cost of goods sold	(€ 334)	(€ 63)	(€ 623)	(€ 115)
Gross profit	€ 601	€ 107	€ 972	€ 240
Research and Development Expense	(€ 3 470)	(€ 2 398)	(€ 7 065)	(€ 5 492)
Selling, General and Administrative Expense	(€ 4 536)	(€ 3 913)	(€ 8 729)	(€ 6 279)
Other income/(expense)	€ 14	(€ 101)	€ 150	(€ 97)
Operating loss for the period	(€ 7 391)	(€ 6 305)	(€ 14 672)	(€ 11 628)
Financial income	€ 4 670	€ 39	€ 6 246	€ 43
Financial expense	(€ 2 162)	(€ 574)	(€ 2 950)	(€ 899)
Loss for the period before taxes	(€ 4 883)	(€ 6 840)	(€ 11 376)	(€ 12 484)
Income taxes	(€ 107)	(€ 99)	(€ 315)	(€ 124)
Loss for the period	(€ 4 990)	(€ 6 939)	(€ 11 691)	(€ 12 608)

Loss attributable to equity holders	(€ 4 990)	(€ 6 939)	(€ 11 691)	(€ 12 608)
Other comprehensive loss
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences	(€ 12)	€ 262	(€ 114)	€ 192
Total comprehensive loss for the year, net of tax	(€ 5 002)	(€ 6 677)	(€ 11 805)	(€ 12 416)
Loss attributable to equity holders	(€ 5 002)	(€ 6 677)	(€ 11 805)	(€ 12 416)

Basic Loss Per Share (in EUR)	(€ 0,193)	(€ 0,314)	(€ 0,453)	(€ 0,570)
Diluted Loss Per Share (in EUR)	(€ 0,193)	(€ 0,314)	(€ 0,453)	(€ 0,570)

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION – INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT JUNE 30, 2022 (in thousands)

	As at
	June 30 2022	December 31 2021
ASSETS
Non-current assets
Property, plant and equipment	€ 2 111	€ 2 020
Intangible assets	32 570	25 322
Right of use assets	3 410	3 218
Deferred tax asset	1 429	46
Other long-term receivables	180	164
	€ 39 700	€ 30 770
Current assets
Inventory	506	346
Trade receivables	957	226
Other receivables	1 548	2 286
Other current assets	852	1 693
Financial assets	47 717	−
Cash and cash equivalents	75 602	135 509
	€ 127 182	€ 140 060
Total assets	€ 166 882	€ 170 830

EQUITY AND LIABILITIES
Capital and reserves
Capital	4 438	4 427
Share premium	228 158	228 033
Share based payment reserve	4 411	3 127
Other comprehensive income	88	202
Retained loss	(98 850)	(87 167)
Total equity attributable to shareholders	€ 138 245	€ 148 622

LIABILITIES
Non-current liabilities
Financial debt	8 089	7 802
Lease liability	2 859	2 737
Pension liability	80	80
Provisions	44	12
Deferred tax liability	−	5
	€ 11 072	€ 10 636
Current liabilities
Financial debt	661	554
Lease liability	672	582
Trade payables	4 301	3 995
Current tax liability	4 391	2 808
Other payables	7 540	3 633
	€ 17 565	€ 11 572
Total liabilities	€ 28 637	€ 22 208
Total equity and liabilities	€ 166 882	€ 170 830

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION – INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS AS AT JUNE 30, 2022 (in thousands)

	For the six months ended June 30
	2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax for the year	€ (11 376)	€ (12 484)
Adjustments for
Finance income	(6 246)	(43)
Finance expenses	2 950	899
Depreciation and impairment of property, plant and equipment and right-of-use assets	536	377
Amortization of intangible assets	402	428
Share-based payment transaction expense	1 292	−
Increase/(Decrease) in provisions	32	−
Other non-cash items	37	11
Cash generated before changes in working capital	€ (12 373)	€ (10 812)
Changes in working capital
Decrease/(Increase) in inventory	(160)	(27)
(Increase)/Decrease in trade and other receivables	1 011	(3 463)
Increase/(Decrease) in trade and other payables	2 053	6 061
Cash generated from changes in operations	€ (9 469)	€ (8 241)
Income tax paid	( 254)	( 111)
Net cash used in operating activities	€ (9 723)	€ (8 352)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment	(302)	(795)
Capitalization of intangible assets	(7 650)	(3 726)
(Increase)/Decrease in financial assets – current	(44 032)	−
Net cash used in investing activities	€ (51 984)	€ (4 521)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of principal portion of lease liabilities	(317)	(236)
Repayment of other loan	(42)	(42)
Interests paid	(134)	(258)
Repayment of recoverable cash advance	−	(105)
Proceeds from issuance of shares, net of transaction costs	136	362
Other financial costs	(8)	(10)
Net cash generated from financing activities	€ (365)	€ (289)
Movement in cash and cash equivalents	€ (62 072)	€ (13 162)
Effect of exchange rates on cash and cash equivalents	2 165	33
Cash and cash equivalents at January 1	€ 135 509	€ 92 300
Cash and cash equivalents at June 30	€ 75 602	€ 79 171

Revenue

Revenue was €935,000 for the second quarter ending June 30, 2022, compared to €170,000 for the second quarter ending June 30, 2021. Revenue for the first half of 2022 was €1.6 million, compared to €355,000 for the first half of 2021. The increase in revenue was attributable to the Company’s commercialization of the Genio® system, primarily in Germany.

Cost of Goods Sold

Cost of goods sold was €334,000 for the three months ending June 30, 2022, representing a gross profit of €601,000, or gross margin of 64.3%. This compares to total cost of goods sold of €63,000 in the second quarter of 2021, for a gross profit of €107,000, or gross margin of 62.9%.

For the six months ending June 30, 2022, total cost of goods sold was €623,000, representing a gross profit of €972,000, or gross margin of 60.9%. This compares to total cost of goods sold of €115,000 in the first half of 2021, for a gross profit of €240,000, or gross margin of 67.6%.

Research and Development Expenses

Research and Development expenses were €3.5 million for the three months ending June 30, 2022, versus €2.4 million for the prior year period, reflecting the Company’s investments in the development of next generation versions of the Genio® system as well as ongoing clinical studies, most notably DREAM in the U.S.

For the six months ending June 30, 2022, Research and Development expenses were €7.1 million, versus €5.5 million for the first half of 2021.

Selling, General and Administrative Expenses

Selling, General and Administrative expenses rose to €4.5 million for the second quarter of 2022, up from €3.9 million in the second quarter of 2021. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

For the six months ending June 30, 2022, Selling, General and Administrative expenses were €8.7 million, up from €6.3 million in the first half of 2021 due to increased commercial efforts in Germany and investments in Nyxoah’s corporate infrastructure.

Operating Loss

Total operating loss for the second quarter and first half of 2022 was €7.4 million and €14.7 million, respectively, versus €6.3 million and €11.6 million in the second quarter and first half of 2021, respectively. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities. Nyxoah realized a net loss of €5.0 million and €11.8 million for the second quarter and first half of 2022, respectively, compared to a net loss of €6.7 million and €12.4 million for the second quarter and first half of 2021, respectively.

Cash Position

As of June 30, 2022, cash and financial assets totaled €123.3 million, compared to €135.5 million on December 31, 2021. Total cash burn was approximately €2.0 million per month during the first half of 2022. Nyxoah expects monthly cash burn to increase in the second half of 2022 to account for the commencement of the ACCCESS IDE trial in the U.S., and the current cash position provides ample liquidity to get to U.S. commercialization in 2024.

First Half 2022 Report

Nyxoah’s financial report for the first half of 2022, including details of the audited consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public today at 10:30 p.m. CET / 4:30 p.m. ET, which will also be webcast. To participate in the conference call, please access the following link to register for a dial-in number: https://register.vevent.com/register/BIfc3a52c9352e4e42958e9d816245b3b9

A question-and-answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com

+1 917 749 14

Attachment

ENGLISH_Q2 2022 Earnings PR Draft Final

August 9, 2022

Pfizer as booster not planned for people aged 16-17: Ministry

The Ministry of Health has no plan to administer the Pfizer COVID-19 vaccine as a booster dose for people in the age bracket of 16-17 years in Indonesia.

“We have not thought of a policy because the (application of) EUA (emergency use authorization) is difficult to be conducted. The operational age is short, 16-17 years. For those aged 18 years, it has already been implemented,” the ministry’s Director General of Disease Prevention and Control, Maxi Rein Rondonuwu, stated when contacted here on Tuesday.

The statement was made in response to the policy of the National Agency of Drug and Food Control (BPOM) that allowed the provision of Pfizer vaccine as booster doses for children aged 16-18 years as of August 2, 2022.

The BPOM stated that Pfizer booster doses could be given at least six months after the second-dose vaccination to children administered the Pfizer vaccine for the first- and second- (homologous) dose vaccinations.

Rondonuwu drew attention to the fact that the homologous booster requirement for the Pfizer vaccine also posed an obstacle since the number of citizens aged 16-17 that had received the Pfizer vaccine for the first- and second-dose vaccinations was relatively small.

He estimated that the number of Pfizer recipients among people in the age group of 16-17 years was less than two million.

“Meanwhile, 90 percent of the adolescents in Indonesia were inoculated with the Sinovac vaccine,” he stated.

According to Rondonuwu, the Ministry of Health is currently pursuing the target of booster coverage for people aged 18 years and above, for which the coverage, so far, has only reached 30 percent. As part of the efforts to boost community immunity against COVID-19, the Indonesian government launched a nationwide vaccination program on January 13, 2021, targeting as many as 208,265,720 citizens across the country.

According to data provided by the COVID-19 Handling Task Force, as of Tuesday, August 9, 2022, as many as 202,772,014 Indonesians had received the first vaccine dose, 170,322,263 had been administered the second dose, and 57,553,217 had taken the booster dose.

Source: Antara News

August 9, 2022

President urges people to not seek medical treatment overseas

President Joko Widodo called on people to desist from seeking treatment overseas, as the government had built modern hospitals in the regions.

“I am very sad to hear that there are people in our country, who fell sick and sought treatment overseas, and for West Kalimantan, there are still many who seek treatment from neighboring countries. Starting today, do not go abroad for treatment anymore, because West Kalimantan already has modern hospitals that can cater to the public,” the president stated after officiating the Soedarso Regional Hospital in Pontianak on Tuesday.

Jokowi said the central and regional governments had worked together to build the Soedarso Hospital Building with modern equipment.

“Earlier, I checked all the conditions of the rooms in this new building. The Soedarso Hospital building has been built using the West Kalimantan Regional Budget since 2019. It has two towers, with six floors each. We have prepared medical equipment in the building at a cost of more than Rp200 billion,” he elaborated.

The head of state noted that the Soedarso Hospital Building had 277 beds and 14 operating rooms. Moreover, the brand-new hospital building was also equipped with ICU, NICU, PICU, and ICCU rooms.

West Kalimantan Governor Sutarmidji conceived the idea of developing the new Soedarso Hospital building, as he was keen that a better hospital be built in West Kalimantan.

This development in the medical sector was also part of the efforts to boost the Human Development Index (HDI).

“I also strongly support the policy of the West Kalimantan provincial government that will handle the operation of the hospital without (discrimination), so that all people get the same, (high) quality services. Hopefully, this hospital would offer great benefits for West Kalimantan’s people, so that they do not seek treatment overseas again,” President Jokowi concluded.

Source: Antara News

August 9, 2022

5.9-magnitude quake hits Maluku Tenggara Barat

An earthquake of magnitude 5.9 hit Maluku Tenggara Barat District, Maluku Province, on Tuesday night, according to the Meteorology, Climatology and Geophysics Agency (BMKG).

The earthquake which struck at 07:59 p.m. West Indonesia Standard Time (WIB) was centered 189 kilometers northwest of Maluku Tenggara Barat at a depth of 176 kilometers.

The epicenter was located at 6.87 degrees southern latitude and 130.00 degrees eastern longitude.

There was no immediate report of casualties or injuries.

Source: Antara News

August 9, 2022

BRIN develops nutritious biscuits to tackle anemia in pregnant women

The National Research and Innovation Agency (BRIN) has created nutritious biscuits for pregnant women to ensure they get adequate nutrition in order to prevent anemia and childhood stunting.

“Nutritious biscuit products have been developed for pregnant women, which also contain soy hydrolyzate, but moringa flour has been added for micronutrients,” expert engineer from BRIN’s Center for Food Technology and Process Research, Noer Laily, said.

Soy hydrolyzate is an ingredient that can be used in several products to increase nutrient absorption and prevent malnutrition, anemia, and childhood stunting.

Mothers who suffer from anemia and have a low body mass index are at risk of giving birth to babies with stunted growth and mental development, Laily said at a webinar on “Talk to Scientists on Research and Innovation for Food and Energy Sovereignty,” which was accessed here on Tuesday.

Since they are made using moringa (Moringa oleifera) flour, the biscuits are rich in micronutrients, such as vitamins and minerals. Moringa is also high in carbohydrates and has active antioxidants, she said.

It is also known for its immunostimulant potential. An immunostimulant is a compound that can modulate the immune system, and thereby, increase the body’s immunity.

Moringa leaves contain macronutrients and micronutrients such as proteins, vitamins A, C, E, B6, thiamine, riboflavin, niacin, and folate, and are rich in minerals such as calcium, phosphorus, sodium, potassium, iron, magnesium, and zinc, she said.

The nutritious biscuits have already been produced on an industrial scale, and currently, they are being tested for efficacy in pregnant women with anemia or chronic energy deficiency. The scale of production has reached 300 kilograms per batch.

The nutritional composition of the biscuits is in accordance with the provision on additional foods for pregnant women stipulated by the Health Minister’s Regulation Number 51 of 2016.

According to the Health Ministry, 5 out of 10 pregnant women in Indonesia who suffer from anemia, or lack of blood, are at risk of giving birth to stunted children.

Stunting is a condition wherein a child fails to get good nutrition or suffers from chronic malnutrition in the early stages of growth. Stunted children are usually shorter than the normal height for their age.

Therefore, it is highly recommended that pregnant women consume nutritious food and supplements to get adequate nutrition.

The government is committed to preventing and resolving the stunting problem to create healthy and high-quality future generations who can contribute their best to national progress and development.

The nutritious biscuits for pregnant women, which have been developed through research and innovation, are proof of the government’s efforts to reduce the stunting rate.

Source: Antara News

August 9, 2022

Ferdy Sambo named suspect in Brigadier J’s death

National Police chief, General Listyo Sigit Prabowo, announced Inspector General Ferdy Sambo as a suspect in the death of Brigadier Nofriansyah Yosua Hutabatara or Brigadier J at the National Police Headquarters in Jakarta on Tuesday.

Earlier, the Special Inspectorate, led by Inspector General of General Supervision (Irwasum), Commissioner General Agung Budi Maryoto, had said that sufficient evidence had been found against Sambo, the former head of the Profession and Security (Propam) Divison of the National Police.

“After an in-depth examination, sufficient evidence has also been found that Sambo has committed a criminal act,” Maryoto informed at the National Police Headquarters on Tuesday night.

He said that on Monday, his team had conducted an in-depth examination of Sambo at the Mobile Brigade Headquarters and found sufficient evidence against him.

“The National Police chief has conveyed that after carrying out the case (investigation), he has been named a suspect,” Maryoto added.

Earlier reports had said that Sambo had been allegedly involved in a gunfight that broke out at his house between Brigadier Hutabarat or Brigadier J and Bhayangkara Two Polri’s Richard Eliezer Pudihang Lumju or Bharada E. Brigadier J was said to have been killed in the gunfight.

However, upon investigation, the police team rejected the shooting scenario. Instead, it concluded that Bharada E shot Brigadier J at Sambo’s request using a weapon belonging to another police officer, Brigadier RR. Meanwhile, Brigadier J’s weapon was allegedly used by Sambo to fire shots at the wall of his house.

There was no evidence of a gunfight at Sambo’s house as reported earlier, Prabowo informed.

“I repeat that there was no evidence of gunfight as reported earlier,” he emphasized.

A number of irregularities reported by the family regarding the wounds on Brigadier J’s body had fuelled public suspicion. A prohibition on the opening of the coffin for traditional rituals, including the absence of official funeral ceremonies, had also stoked people’s curiosity.

Source: Antara News